Global In-Silico Drug Discovery Market – Industry Trends and Forecast to 2030

Global In-Silico Drug Discovery Market, By Type (Software as a Service, Consultancy as a Service, Software), Type of Large Molecule (Antibodies, Proteins, Peptides, Nucleic Acids, Vectors), Workflow (Discovery, Target Identification, Reverse Docking, Bioinformatics, Protein Structure Prediction, Target Validation, Lead Discovery, Pharmacophore, Library Design, Preclinical Tests, Clinical Trials), Target Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Mental Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Skin Disorders, Urogenital Disorders, Autoimmune Disorders, Blood Disorders, Cardiovascular Disorders, Gastrointestinal and Digestive Disorders, Hormonal Disorders, Others), End User (Contract Research Organizations, Pharmaceutical Industry, Academic and Research Institutes, Others) - Industry Trends and Forecast to 2030.

In-Silico Drug Discovery Market Analysis and Size

The global in-silico drug discovery methods usually help to find drug targets through bioinformatics tools. These methods can also be used to analyze target structures for possible binding sites, generate candidate molecules, check for their drug-likeness, rank them according to their binding affinities, dock these molecules with the target, and further optimize molecules to progress binding characteristics.

The rise in the volume of drug discovery data is among the important factors expected to intensify the growth and demand of the market. In addition, the rise in the growth in the biomarker identification area and the focus on reduction in readmission rates and medical errors are expected to contribute to market growth over the forecast period of 2023 to 2030. The computational technological advancements in the field of computational biology and rapid advancements in in-silico drug discovery techniques are also likely to enhance market growth. Furthermore, the cost-effectiveness and the high adoption of in-silico drug designing services are among the significant factors expected to fuel market growth.

Data Bridge Market Research analyzes that the global in-silico drug discovery market was valued at USD 3,394.8 billion in 2022 and is further estimated to reach USD 9,415.44 billion by 2030, and is expected to grow at a CAGR of 13.6% during the forecast period of 2023 to 2030. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In-Silico Drug Discovery Market Scope and Segmentation

Market Definition

The global in-silico drug discovery market is the market for computational methods and tools used in new drug discovery and development. Computational simulation, modeling, and informatics are used to analyze and predict the behavior of potential drug compounds and their interactions with biological targets. In-silico drug discovery offers a cost-effective and time-efficient alternative to traditional experimental approaches, enabling researchers to prioritize and optimize potential drug candidates before progressing to in vitro and in vivo testing.

Global In-Silico Drug Discovery Market Dynamics

Drivers

• Increasing Drug Development Costs

The high costs associated with traditional drug development methods, including extensive laboratory testing and clinical trials, have led pharmaceutical companies to adopt in-silico pharmaceutical discovery techniques. These methods offer significant savings by reducing the number of compounds to be synthesized and experimentally tested.

• Advances in Computational Power

The continuous development of computing power has significantly improved the possibilities of in-silico drug discovery. High-performance computing enables faster and more accurate simulations, molecular modeling, virtual screening, and big data analysis, accelerating drug discovery.

• Growing Demand for Personalized Medicine

The shift to personalized medicine, which aims to develop personalized treatments based on an individual's genetic profile, has increased the demand for in silico drug development. Computational approaches can analyze genomic data and identify potential drug targets or individually predict certain drugs' effectiveness and side effects.

Opportunities

• Rise of Artificial Intelligence (AI) and Machine Learning (ML)

The integration of AI , and ML algorithms in in-silico drug discovery holds immense potential. These technologies can improve the accuracy of virtual screening, lead optimization, and prediction of drug-target interactions, leading to more efficient drug development processes.

• Adoption of Cloud Computing

Cloud computing platforms offer scalable and cost-effective solutions for managing and analyzing large volumes of data generated in in-silico drug discovery. Cloud-based infrastructure facilitates collaboration, data sharing, and access to specialized tools, enhancing research efficiency and productivity.

Restraints/Challenges

• Regulatory Challenges

In-silico drug development faces regulatory challenges in validating and accepting the results of computational models and virtual screening as reliable predictors of real-world outcomes. Regulatory authorities must establish guidelines for integrating in-silico approaches into drug discovery.

• Integration with Experimental Validation

While in-silico drug discovery can accelerate the early stages of drug development, experimental validation remains crucial for ensuring the safety and efficacy of potential drug candidates. Bridging the gap between computational predictions and experimental results poses a significant challenge in the field.

The global in-silico drug discovery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In April 2021, an Italian startup, InSilicoTrials Technologies, received funding for its 3 Horizon 2020 project by the EU to support the development of advanced medical devices through in silico trials. Such actions are expected to improve the market growth of computer simulation trials for medical devices in the future
• In December 2020, BioMed Central published a research study in which computer simulation trials were used for testing the COVID-19 vaccine. Such actions are likely to have a positive impact on market growth. However, low awareness about in silico trials in developing economies and issues related to protein flexibility, molecule conformation, and promiscuity leading to inaccurate prediction may hinder the demand for computer simulation trials.

Global In-Silico Drug Discovery Market Scope

The global in-silico drug discovery market is segmented into five notable segments based on type, type of large molecule, workflow, target therapeutic area, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Software as a service
• Consultancy as a service
• Software

Type of Large Molecule

• Antibodies
• Proteins
• Peptides
• Nucleic acids
• Vectors

Workflow                                          

• Discovery
• Target identification
• Reverse docking
• Bioinformatics
• Protein structure prediction
• Target validation
• Lead discovery
• Pharmacophore
• Library design
• Preclinical tests
• Clinical Trials

Target Therapeutic Area

• Human Immunodeficiency Virus (HIV)
• Infectious diseases
• Metabolic disorders
• Mental disorders
• Musculoskeletal disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Skin disorders
• Urogenital disorders
• Autoimmune disorders
• Blood disorders
• Cardiovascular disorders
• Gastrointestinal and digestive disorders
• Hormonal disorders
• Others

End User

• Contract research organizations
• Pharmaceutical industry
• Academic and research institutes
• Others

Global In-Silico Drug Discovery Market Regional Analysis/Insights

The global in-silico drug discovery market is analyzed and market size insights and trends are provided by country, type, type of large molecule, workflow, target therapeutic area, and end user as referenced above.

The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

North America is expected to dominate the market owing to the rapid technological advancements, strong presence of strong vendors and large patient population suffering from various chronic and Infectious Diseases.

Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2023 to 2030 due to the rise in the number of academics and extensive research in cancer and diabetes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global in-silico drug discovery market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2020.

Competitive Landscape and Global In-Silico Drug Discovery Market Share Analysis

The global in-silico drug discovery market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major market players operating in the global in-silico drug discovery market are:

• Curia Global Inc. (U.S.)
• Certara, USA (U.S.)
• Charles River Laboratories (U.S.)
• Chemical Computing Group ULC (U.S.)
• GenScript (U.S.)
• Sygnature Discovery (U.K.)
• Abzena Ltd.(U.S.)
• BioNTech SE (Germany)
• Creative Biostructure (U.S.)